| 蔡强军,潘芙蓉,张琦,等.131I对Graves病外周血粒细胞集落刺激因子和白细胞的影响[J].中华放射医学与防护杂志,2011,31(6):668-670.CAI Qiang-jun,PAN Fu-rong,ZHANG Qi,et al.Effects of 131I treatment on the circulating granulocyte colony-stimulating factor and leucocyte levels in patients with Graves' disease[J].Chin J Radiol Med Prot,2011,31(6):668-670 |
| 131I对Graves病外周血粒细胞集落刺激因子和白细胞的影响 |
| Effects of 131I treatment on the circulating granulocyte colony-stimulating factor and leucocyte levels in patients with Graves' disease |
| 投稿时间：2011-02-18 |
| DOI：10.3760/cma.j.issn.0254-5098.2011.06.012 |
| 中文关键词: Graves病 粒细胞集落刺激因子 白细胞减少 131I治疗 |
| 英文关键词:Graves' disease Granulocyte colony-stimulating factor Leucopenia 131I treatment |
| 基金项目:温州市"新世纪551人才工程"基金(551-02) |
|
| 摘要点击次数: 4467 |
| 全文下载次数: 2437 |
| 中文摘要: |
| 目的 探讨131I治疗Graves病(GD)对患者外周血粒细胞集落刺激因子(G-CSF)和白细胞的影响。方法 采用酶联免疫吸附试验(ELISA)、Coulter 3分类血细胞分析和放射免疫分析法(RIA),分别检测初发43例白细胞正常和22例白细胞减少的GD患者于131I治疗前及治疗后30、90和180 ｄ血清G-CSF水平、白细胞总数和甲状腺激素水平,并进行相关性分析。30例年龄与性别相匹配的健康者作为健康对照。结果 GD患者中白细胞正常组血清G-CSF水平(28.4±11.7)μg/L显著高于健康对照组(18.3±6.98)μg/L (t=2.376,P<0.05);白细胞减少组血清G-CSF水平(40.1±13.8)μg/L升高(t=3.672,P<0.01);131I治疗180 ｄ后,甲状腺功能恢复正常,症状缓解,血清G-CSF水平逐渐下降,但白细胞减少组(25.7±11.5) μg/L仍高于健康对照组(t=2.103,P<0.05);GD患者G-CSF与白细胞呈负相关(r=-0.38,P<0.05),与FT3、FT4、TSH没有相关性。 结论 GD患者体内存在G-CSF异常表达,可能与白细胞减少有关;131I治疗能有效抑制GD患者自身免疫,可能是治疗伴白细胞减少GD患者一种安全可靠、疗效显著的方法,宜尽早选用。 |
| 英文摘要: |
| Objective To observe the effects of 131I treatment on circulating granulocyte colony-stimulating factor (G-CSF) and leucocyte levels of patients with Graves' disease (GD). Methods Enzyme-linked immunosorbent assay (ELISA), coulter three assortments, and radioimmunoassay were used to test the levels of circulating G-CSF, leucocytes and thyroid hormones of 65 incipient and untreated GD patients, all females, aged 21-50, 43 with normal leucocyte level and 22 with leucopenia before and after 131I treatment. Thirty age-matched healthy female subjects were used as controls. Results Before 131I treatment, the serous G-CSF level of the GD patients with normal leucocyte level was (28.4±11.7)μg/L, significantly higher than that of the control [(18.3±6.98) μg/L, t=2.376,P<0.05]. The serous G-CSF level of the GD patients with leucopenia was (40.1±13.8) μg/L, significantly higher than that of the patients with normal leucocyte level (t=2.788,P<0.01) and that of the control (t=3.672, P<0.01). 180 d after the initiation of 131I treatment, the G-CSF level of the patients with normal leucocyte level was (18.9±8.32) μg/L, not significantly different from that of the normal controls, however, the G-CSF level of the GD patients with leucopenia was (25.7±11.5) μg/L, still significantly higher than that of the normal control (t=2.103, P<0.05). The serous G-CSF level was negatively correlated with the titer of leucocyte (r=-0.38, P<0.05), however, not significantly correlated with such clinical parameters, as free triiodothyronine (FT3), free thyroxine (FT4) and thyrotropin-stimulating hormone (TSH). Conclusions Abnormal increment of G-CSF is observed in the GD patients, which may be related to the decrease of leucocyte. Effectively suppressing the auto-immune status in the GD patients, 131I treatment is a safe and reliable therapy for GD patients with leucopenia and should be used as early as possible. |
| HTML 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|